TARA: Quarterly Losses Grow as Trial Costs Rise and TARA-002 Production Moves In-House
TARA's third-quarter losses widened on higher trial spending. The company held $143.1M in cash and marketable securities, with THRIVE-3 interim data due in Q4.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, biotech company TARA reported wider losses for the third quarter as spending on clinical trials and CMC, the manufacturing side of development, went up. At the end of the period the company held $143.1M in cash and marketable securities.
Near-term milestones include THRIVE-3 interim results, which are expected in the fourth quarter. Shortly after the period ended, TARA also agreed to acquire TARA-002 manufacturing for $8.75M, meaning the drug will now be produced in-house.
why it matters
Investors are weighing two things here: how fast spending is climbing and how much liquidity the company has to fund it. The THRIVE-3 results will be the main reference point for the market, since they will show how far the development program has progressed.
market impact
TARA: rising losses and development costs put pressure on the company's shares
tags
instruments
sources
- TARA: Wider losses fund pipeline growth as TARA-002 manufacturing moves in-house — TradingView, 6 November 2026 at 13:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗